Key result
Beta-blockers remain the cornerstone of therapy for CPVT, with flecainide, left cardiac sympathetic denervation, and ICDs serving as additive or alternative options for refractory cases.
Why the study?
The review aims to summarize the arrhythmogenic mechanisms, current therapeutic management, and potential future perspectives for catecholaminergic polymorphic ventricular tachycardia.
Design
Review
Authors
Loading...
CPVT genetic insights support current beta-blocker use; leaves open targeted therapies for mutation-specific risk.
This review highlights that while beta-blockers are the primary treatment for CPVT, flecainide and left cardiac sympathetic denervation are important adjunctive therapies, and ICDs must be used with extreme caution to avoid shock-induced electrical storms.
Baltogiannis et al. (2019) conducted a review in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Therapeutic management (Beta blockers, Flecainide, LCSD, ICD) was evaluated. Beta-blockers remain the cornerstone of therapy for CPVT, with flecainide, left cardiac sympathetic denervation, and ICDs serving as additive or alternative options for refractory cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: